International Journal of Hematology最新文献_第2页

Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia. 诺妥珠单抗ozogamicin预防唐氏综合征和复发性急性淋巴细胞白血病的男孩复发。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-09 DOI: 10.1007/s12185-024-03890-1

Atsushi Kohso, Hidemi Toyoda, Ryo Hanaki, Kaori Niwa, Yosuke Okumura, Mari Morimoto, Takahiro Ito, Masahiro Hirayama

{"title":"Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia.","authors":"Atsushi Kohso, Hidemi Toyoda, Ryo Hanaki, Kaori Niwa, Yosuke Okumura, Mari Morimoto, Takahiro Ito, Masahiro Hirayama","doi":"10.1007/s12185-024-03890-1","DOIUrl":"10.1007/s12185-024-03890-1","url":null,"abstract":"Inotuzumab ozogamicin (InO), a CD22-directed antibody conjugated to calicheamicin, has demonstrated excellent efficacy in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). It has been used for patients with relapsed or refractory BCP-ALL as a bridge to allo-HCT. Children with Down syndrome (DS) have an increased risk of BCP-ALL and higher rates of relapse and toxicity, including treatment-related mortality. Although allo-HCT is potentially curative for relapsed or refractory ALL, post-transplant leukemic relapse rates and transplant-related mortality are dismal in patients with DS-ALL, which results in less frequent use of allo-HCT in this group than in the non-DS population. Therefore, novel and less toxic therapeutic strategies are required to improve outcomes. Here we report the case of a child with DS who was diagnosed with a second relapse of BCP-ALL and has maintained complete remission through regular single-agent InO therapy. Single-agent maintenance using InO can be a good option to avoid subsequent relapse in patients with relapsed or refractory BCP-ALL who cannot proceed to allo-HCT and require less-toxic treatments.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"276-280"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis. 血液透析慢性髓性白血病患者服用阿西米尼的安全性和有效性。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-11-07 DOI: 10.1007/s12185-024-03869-y

Ryosuke Naka, Yoshimitsu Shimomura, Masatomo Miura, Yuya Nagai, Tadakazu Kondo, Takayuki Ishikawa

{"title":"Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis.","authors":"Ryosuke Naka, Yoshimitsu Shimomura, Masatomo Miura, Yuya Nagai, Tadakazu Kondo, Takayuki Ishikawa","doi":"10.1007/s12185-024-03869-y","DOIUrl":"10.1007/s12185-024-03869-y","url":null,"abstract":"The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML), significantly improving patient prognosis. Asciminib, a novel specifically targeting the ABL myristoyl pocket inhibitor, has shown promise for CML patients unresponsive or intolerant to traditional TKIs. However, its use in hemodialysis patients remains underexplored. We present a case of a 71-year-old man with CML undergoing hemodialysis, successfully treated with asciminib. Initial treatment with bosutinib was effective but later failed, prompting a switch to asciminib. The patient achieved a major molecular response within 2 months without adverse effects. Pharmacokinetic analysis revealed significant drug clearance during hemodialysis, necessitating dosage adjustments. This case highlights the potential of asciminib in managing CML in hemodialysis patients, emphasizing the need for individualized treatment plans and close monitoring. Further studies are warranted to establish comprehensive guidelines for asciminib use in this unique patient population.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"272-275"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia. 阿西米尼对重度预处理慢性髓性白血病患者的实际毒性和疗效。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-11-19 DOI: 10.1007/s12185-024-03873-2

Yoshimi Ishii, Shin Fujisawa, Takuya Miyazaki, Yuki Nakajima, Ayako Matsumura, Katsumichi Fujimaki, Taisei Suzuki, Maki Hagihara, Marika Tanaka, Chizuko Hashimoto, Hideaki Nakajima

{"title":"Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia.","authors":"Yoshimi Ishii, Shin Fujisawa, Takuya Miyazaki, Yuki Nakajima, Ayako Matsumura, Katsumichi Fujimaki, Taisei Suzuki, Maki Hagihara, Marika Tanaka, Chizuko Hashimoto, Hideaki Nakajima","doi":"10.1007/s12185-024-03873-2","DOIUrl":"10.1007/s12185-024-03873-2","url":null,"abstract":"Although tyrosine kinase inhibitors (TKIs) have improved the prognosis of chronic myeloid leukemia (CML), some patients do not respond to TKIs. We evaluated 21 patients with CML treated with asciminib, which is effective in heavily pretreated patients. The median age was 63 years (range 25-82). Fourteen patients (67%) had been treated with at least three TKIs (range 2-5 prior lines). The switch to asciminib was due to intolerance in 14 patients (67%) and failure in seven patients (33%). The median duration of asciminib exposure was 237 days. With a median follow-up of 273 days, three patients (14%) discontinued asciminib due to failure and two (10%) due to intolerance. Among the 20 evaluable patients, the cumulative rates of molecular response with a two-log reduction, major molecular response, and four-log reduction were 80%, 60%, and 15%, respectively. The six-month event-free survival rate was 74.7%. The most frequent adverse events were liver dysfunction (29%), elevated amylase levels (14%), and renal dysfunction (10%). No patient experienced cardiovascular events. Six patients (29%) experienced cross-intolerance to asciminib, a rate similar to that for previous TKIs. Our study supports the efficacy and tolerability of asciminib in heavily pretreated CML patients in real-world settings.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"187-193"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clot waveform analysis-based system for differential diagnosis of prolonged activated partial thromboplastin time in plasma samples. 血浆样本中活化部分凝血活酶时间延长的血块波形分析为基础的鉴别诊断系统。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-05 DOI: 10.1007/s12185-024-03883-0

Naruto Shimonishi, Kenichi Ogiwara, Kengo Onishi, Toshiki Kawabe, Tomohisa Nishio, Keiji Nogami

{"title":"A clot waveform analysis-based system for differential diagnosis of prolonged activated partial thromboplastin time in plasma samples.","authors":"Naruto Shimonishi, Kenichi Ogiwara, Kengo Onishi, Toshiki Kawabe, Tomohisa Nishio, Keiji Nogami","doi":"10.1007/s12185-024-03883-0","DOIUrl":"10.1007/s12185-024-03883-0","url":null,"abstract":"Introduction: Prolonged activated partial thromboplastin time (aPTT) in plasma samples requires quick and accurate differential diagnosis. We developed two methods using clot waveform analysis (CWA) for plasma samples with prolonged aPTT, particularly for factor (F)VIII deficiency. One method estimates FVIII activity (FVIII:C) using CWA without measuring FVIII:C by template matching. The other utilizes CWA in the mixing test to quickly differentiate FVIII deficiency (FD), FVIII inhibitor (Inh), and lupus anticoagulant (LA).Aim: To establish a more accurate system for differential diagnosis of aPTT prolongation, including FIX deficiency, by combining a CWA-based mixing test and template matching.Methods: Samples with FD (n = 96), LA (n = 19), and Inh (n = 28) were incubated with normal plasma. FD, LA, and Inh were differentiated using a mixing test, followed by CWA-based template matching.Results: In the mixing test, sensitivity for FD, Inh, and LA was 100%, 93%, and 100%, and specificity was 96%, 100%, and 100%. Samples with FIX inhibitor (> 0.6 BU/mL) were differentiated as the inhibitor sample. In template matching, almost all severe hemophilia A and B were judged as the respective severe types.Conclusion: This novel CWA-based measurement system could aid in differential diagnosis of prolonged aPTT.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"151-160"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature. 急性髓性白血病合并NUP98::RARG重排1例报告及相关文献复习

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-04 DOI: 10.1007/s12185-024-03881-2

Junki Inamura, Takeshi Taketani, Miho Mochida, Tsukimi Goto, Ritsuro Suzuki, Sho Igarashi, Nodoka Tsukada, Masayo Yamamoto, Motohiro Shindo, Kazuya Sato

{"title":"Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.","authors":"Junki Inamura, Takeshi Taketani, Miho Mochida, Tsukimi Goto, Ritsuro Suzuki, Sho Igarashi, Nodoka Tsukada, Masayo Yamamoto, Motohiro Shindo, Kazuya Sato","doi":"10.1007/s12185-024-03881-2","DOIUrl":"10.1007/s12185-024-03881-2","url":null,"abstract":"We herein report a rare case of acute myeloid leukemia (AML) with t(11;12)(p15;q13) and NUP98::RARG, which seems to be involved in the development of AML. The morphological features were similar to those of classic acute promyelocytic leukemia (APL), but unlike classic APL, this leukemia was resistant to treatment with all-trans retinoic acid (ATRA). We decided to use standard chemotherapy for AML with monitoring of minimal residual disease (MRD) by qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for NUP98::RARG mRNA. Although MRD disappeared after induction chemotherapy, it later reappeared, and hematological relapse occurred during subsequent chemotherapies. The patient received haploidentical hematopoietic stem cell transplantation while not in remission and achieved a second molecular remission. However, relapse occurred 4 months after transplantation. The specific mechanism of ATRA resistance in this unique case of AML remains unclear, and no standard treatment has been determined. This is the first case report of AML with NUP98::RARG rearrangement in Japan. Qualitative RT-PCR analysis for NUP98::RARG mRNA was helpful for the accurate diagnosis and evaluation of MRD to choose an adequate treatment for this type of AML.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"265-271"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB. OTUD7B表达减少与PTCL不良预后相关，其途径为非典型NF-κB。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-05 DOI: 10.1007/s12185-024-03877-y

Feng Chen, Shi Qiu, Ailing Gui, Shiyu Jiang, Yichen Yan, Jichuan Wu, Guangliang Chen, Shun Zhu, Yizhen Liu, Zuguang Xia, Baohua Yu, Xiaojian Sun, Juan Jennifer Gu, Lan Wang, Wen Liu, Ling Yang, Qunling Zhang, Ji Zuo

{"title":"Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.","authors":"Feng Chen, Shi Qiu, Ailing Gui, Shiyu Jiang, Yichen Yan, Jichuan Wu, Guangliang Chen, Shun Zhu, Yizhen Liu, Zuguang Xia, Baohua Yu, Xiaojian Sun, Juan Jennifer Gu, Lan Wang, Wen Liu, Ling Yang, Qunling Zhang, Ji Zuo","doi":"10.1007/s12185-024-03877-y","DOIUrl":"10.1007/s12185-024-03877-y","url":null,"abstract":"Peripheral T cell lymphoma (PTCL) is an aggressive and highly heterogeneous lymphoma with a bleak prognosis, highlighting the urgent need for an effective biomarker to guide therapeutic strategies. Ovarian tumor domain-containing 7B (OTUD7B) has been shown to have a critical function in the progression of cancers. However, the prognostic significance of OTUD7B in PTCL remains unexplored. In this study, we demonstrated for the first time that PTCL patients with low expression of OTUD7B had shorter progression-free survival (PFS) and overall survival (OS). In addition, OTUD7B knockdown promoted chemoresistance to doxorubicin in PTCL cell lines, and led to increased translocation of p52 from the cytoplasm to the nucleus. Inhibition of non-canonical NF-κB partially restored the sensitivity of PTCL cells to doxorubicin. Remarkably, 5-azacytidine and cytarabine upregulated the expression of OTUD7B and exhibited a synergistic anti-lymphoma effect in PTCL. In summary, our study confirmed the prognostic role of OTUD7B in PTCL and the promising therapeutic potential of combining 5-azacytidine or cytarabine and doxorubicin for PTCL treatment.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"194-205"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma. dream -11， Part 2：贝兰他单抗-马弗多汀联合治疗复发/难治性多发性骨髓瘤的日本I期临床试验

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-24 DOI: 10.1007/s12185-024-03889-8

Kazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada, Taku Fujii, Hitomi Kato, Ryuichi Fukushima, Satoshi Wakabayashi, Hirofumi Nakano, Sumita Roy-Ghanta, Brandon E Kremer

{"title":"DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.","authors":"Kazutaka Sunami, Shinsuke Iida, Nobuhiro Tsukada, Taku Fujii, Hitomi Kato, Ryuichi Fukushima, Satoshi Wakabayashi, Hirofumi Nakano, Sumita Roy-Ghanta, Brandon E Kremer","doi":"10.1007/s12185-024-03889-8","DOIUrl":"10.1007/s12185-024-03889-8","url":null,"abstract":"DREAMM-11 (NCT03828292) was a Phase 1, open-label, dose-escalation study of belantamab mafodotin in Japanese patients with relapsed/refractory multiple myeloma (RRMM). In Part 1, belantamab mafodotin monotherapy (2.5 or 3.4 mg/kg every 3 weeks) was tolerated and demonstrated clinical activity and a manageable safety profile. Part 2 investigated the tolerability, safety, clinical activity and pharmacokinetics of belantamab mafodotin (2.5 mg/kg on Day [D]1 of each 21-day cycle) plus bortezomib and dexamethasone (Arm A; N = 3) or belantamab mafodotin (2.5 mg/kg on D1 of the first 28-day cycle; 1.9 mg/kg on D1 of subsequent cycles) plus pomalidomide and dexamethasone (Arm B; N = 4) in Japanese patients with RRMM and ≥ 1 prior line of therapy. No dose-limiting toxicities were reported in Arm A; 1 (non-serious liver injury) was reported in Arm B. Safety profiles of each treatment combination were consistent with those of the individual agents and those in Western populations. An overall response was achieved by 3/3 (100%) patients in Arm A and 2/4 (50%) in Arm B. Pharmacokinetics were consistent between Japanese and Western populations. The clinical pharmacokinetics, safety, and efficacy data from this study can inform future use of belantamab mafodotin plus bortezomib/pomalidomide and dexamethasone in Japanese patients with RRMM.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"174-186"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma. 成人 T 细胞白血病/淋巴瘤中 NOTCH1 和 FBXW7 改变的临床意义。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-11-25 DOI: 10.1007/s12185-024-03880-3

Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Eiichi Ohtsuka, Morishige Takeshita, Reiji Muto, Ilseung Choi, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Youko Suehiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki

{"title":"Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.","authors":"Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Eiichi Ohtsuka, Morishige Takeshita, Reiji Muto, Ilseung Choi, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Youko Suehiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki","doi":"10.1007/s12185-024-03880-3","DOIUrl":"10.1007/s12185-024-03880-3","url":null,"abstract":"Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which 33 were single nucleotide variants/insertion-deletions in the PEST domain, and 7 were in the heterodimerization or LIN-12/Notch repeats domains. FBXW7 alterations were observed in nine ATLL patients (3.5%). For patients without allogeneic hematopoietic stem cell transplantation (HSCT), NOTCH1, but not FBXW7, alterations were significantly and independently associated with worse overall survival (median OS 0.5 years, 95% confidence interval [CI] 0.4-0.5 years for 27 patients with NOTCH1 alterations vs 1.8 years, 95% CI 1.3-2.2 years for 170 patients without). Also, for patients receiving mogamulizumab, but not allogeneic-HSCT, NOTCH1, but not FBXW7, alterations were significantly associated with worse survival (median survival from the first dose of mogamulizumab 0.4 years, 95% CI 0.3-0.5 years for 12 patients with NOTCH1 alterations vs 1.4 years, 95% CI 0.9-2.0 years for 87 without). In contrast, NOTCH1 alterations had no significant impact on survival of patients who did receive allogeneic-HSCT. Thus, mogamulizumab-containing treatment was unable to overcome treatment refractoriness of ATLL with NOTCH1 alterations. Therefore, patients with NOTCH1 alterations are recommended for allogeneic-HSCT.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"206-221"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nodal mature plasmacytoid dendritic cell proliferation mimicking lymphoma in a patient with CALR-mutated myelofibrosis. 一名 CALR 基因突变骨髓纤维化患者体内模仿淋巴瘤的结节性成熟浆细胞树突状细胞增殖。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-31 DOI: 10.1007/s12185-024-03902-0

Francesca Magnoli, Marco Brociner, Stefano La Rosa

引用次数: 0

Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors. 异基因 SCT 与 tisagenlecleucel 对 R/R LBCL 和预后不良患者的治疗效果。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-01 Epub Date: 2024-12-16 DOI: 10.1007/s12185-024-03888-9

Kenta Hayashino, Toshiki Terao, Hisakazu Nishimori, Wataru Kitamura, Hiroki Kobayashi, Chihiro Kamoi, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

{"title":"Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors.","authors":"Kenta Hayashino, Toshiki Terao, Hisakazu Nishimori, Wataru Kitamura, Hiroki Kobayashi, Chihiro Kamoi, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda","doi":"10.1007/s12185-024-03888-9","DOIUrl":"10.1007/s12185-024-03888-9","url":null,"abstract":"This study investigated the efficacy of tisagenlecleucel (tisa-cel) and allogeneic hematopoietic stem cell transplantation (allo-SCT) for patients with relapsed and/or refractory (r/r) large B-cell lymphoma (LBCL) with poor prognostic factors, defined as performance status (PS) ≥ 2, multiple extranodal lesions (EN), chemorefractory disease, or higher lactate dehydrogenase (LDH). Overall, the allo-SCT group demonstrated worse progression-free survival (PFS), higher non-relapse mortality, and a similar relapse/progression rate. Notably, the tisa-cel group showed better PFS than the allo-SCT group among patients with chemorefractory disease (3.2 vs. 2.0 months, p = 0.092) or higher LDH (4.0 vs. 2.0 months, p = 0.018), whereas PFS in the two cellular therapy groups was similar among those with PS ≥ 2 or multiple EN. Survival time after relapse post-cellular therapy in patients with poor prognostic factors was 1.6 with allo-SCT and 4.6 months with tisa-cel. These findings were confirmed in a propensity score matching cohort. In conclusion, tisa-cel resulted in better survival than allo-SCT in patients with poor prognostic factors. However, patients who relapsed post-cellular therapy had dismal outcomes regardless of therapy. Further strategies are warranted to improve outcomes in these patients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"232-243"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0